All In Biotech

Drug Trial Radar · NCT06801223

A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection

A Multicenter, Open-label, Phase 1b Study to Assess the Pharmacokinetics, Safety, and Tolerability of Sulbactam-Durlobactam in Hospitalized Pediatric Patients From Birth to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Acinetobacter Baumannii-calcoaceticus Complex Infection

Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Dec 30, 2026

Primary completion

May 5, 2028

Study completion May 20, 2028

Sponsor

Sponsor type
Industry
Collaborators
Entasis Therapeutics
First posted
Jan 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 day, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to investigate the use of Sulbactam-Durlobactam (SUL-DUR) in pediatric patients and is being conducted to collect pharmacokinetic (PK) and safety data to enable the identification of appropriate pediatric dosing regimens for patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections

Conditions

  • Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)

Interventions

  • Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours)Drug

    25mg/kg SUL and 25mg/kg DUR

  • Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours)Drug

    20mg/kg SUL and 20mg/kg DUR

  • Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 8 hours)Drug

    25mg/kg SUL and 25mg/kg DUR

  • Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 12 hours)Drug

    20mg/kg SUL and 20mg/kg DUR

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assess the pharmacokinetic (PK) parameters for maximum concentration (Cmax) of sulbactam and durlobactamTime frame: Day 1 and Day 3
  2. Assess the PK parameters for area under the plasma concentration-time curve from 0 to 24 hours (AUC 0-24) of sulbactam and durlobactamTime frame: Day 1 and Day 3

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • UCLA Medical Center

    Los Angeles, California · Recruiting

  • Rady Children's Hospital

    San Diego, California · Recruiting

  • ECU Brody School of Medicine

    Greenville, North Carolina · Recruiting

  • University of Texas Medical Branch at Galveston

    Galveston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.